CM5321s Common Cold Treatment
What is involved with this trial?
CM5321 is trialling a potential treatment for the common cold. For this trial, the study drug will be administered as a nasal spray. Your participation will involve a visit to our Fullarton Clinic and completing questionnaires via a mobile app.
Why is this research important?
Each year the common cold effects millions of people worldwide, however most medications treat the symptoms not the cause of the cold. CMAX and Fusion Clinical Research are now trialling a potential new treatment for common cold viruses, rather than just treating symptoms.
- Age: 18-65
- Sex: Males & Females
- Medication: Must not be taking any medications to treat cold symptoms
- Medical History: Recent onset cold symptoms within the past 36 hours
- 1 Visit, 2 week participation period
How to apply
To register your interest in this trial, please complete this form. A Fusion team member will be in contact to discuss your eligibility shortly.